Harrow Health/$HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Ticker
$HROW
Sector
Primary listing
Employees
373
Headquarters
Website
Harrow Health Metrics
BasicAdvanced
$1.4B
-
-$0.14
0.10
-
Price and volume
Market cap
$1.4B
Beta
0.1
52-week high
$54.85
52-week low
$20.85
Average daily volume
858K
Financial strength
Current ratio
2.199
Quick ratio
1.931
Long term debt to equity
482.02
Total debt to equity
483.723
Interest coverage (TTM)
1.26%
Profitability
EBITDA (TTM)
48.821
Gross margin (TTM)
75.05%
Net profit margin (TTM)
-1.89%
Operating margin (TTM)
11.21%
Effective tax rate (TTM)
-275.66%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
4.84%
Return on equity (TTM)
-8.47%
Valuation
Price to revenue (TTM)
4.987
Price to book
26.22
Price to tangible book (TTM)
-11.07
Price to free cash flow (TTM)
31.756
Free cash flow yield (TTM)
3.15%
Free cash flow per share (TTM)
1.163
Growth
Revenue change (TTM)
36.41%
Earnings per share change (TTM)
-71.49%
3-year revenue growth (CAGR)
45.39%
10-year revenue growth (CAGR)
39.56%
3-year earnings per share growth (CAGR)
-35.17%
10-year earnings per share growth (CAGR)
-21.92%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $1.4B as of March 12, 2026.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of March 12, 2026.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of March 12, 2026.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.